Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial
Yeh, Yung-Sung, Tsai, Hsiang-Lin, Huang, Ching-Wen, Wang, Jui-Ho, Lin, Yi-Wen, Tang, Hsiu-Chih, Sung, Yung-Chuan, Wu, Chang-Chieh, Lu, Chien-Yu, Wang, Jaw-YuanVolume:
17
Language:
english
Journal:
Trials
DOI:
10.1186/s13063-016-1153-3
Date:
December, 2016
File:
PDF, 541 KB
english, 2016